Covalent bonding of magnetic Fe3O4 nanoparticles to aminopropyl‐functionalized magnesium phyllosilicate clay: Synthesis and cytotoxic potential investigation. (15th September 2017)

• Record Type: Journal Article
• Authors: Nasrabadi, Hasan; Amirghofran, Zahra; Esmaeilbeig, Ahmadreza; Bahrami, Mehrangiz; Jafar Hoseini, S.
• Is Part Of: Applied organometallic chemistry. Volume 32:Number 2(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-09-15
• Subjects: aminoclay -- anticancer drug -- magnetic Fe3O4 nanoparticle; Organometallic chemistry -- Periodicals; Organometallic compounds -- Periodicals; 547.05
• DOI: 10.1002/aoc.4036
• Languages: English
• ISSNs: 0268-2605

Abstract

Abstract : Stable water dispersion of Fe3 O4 magnetic nanoparticles (NPs) were successfully synthesized by using 3‐glycidoxypropyltrimethoxysilane (GPTMS) and Mg‐phyllo (organo) silicate known as aminoclay (AC) containing pendant amino groups with the approximate composition (R8 Si8 Mg6 O16 (OH)4, R = CH2 CH2 CH2 NH2 ). The Fe3 O4 ‐GPTMS magnetic NPs with an epoxy functional group are suitable for forming a covalent bond with the amine group of aminoclay in an epoxy ring opening reaction. Appropriate Fe3 O4 ‐GPTMS‐aminoclay (FG‐AC) magnetic composite are promising carriers for the targeting and delivery of platinum‐based anticancer drugs. Analysis of the cytotoxicity of the nanostructures on a K562 leukemia cell line using a colorimetery assay shows that both the FG‐AC and cis ‐platin/FG‐AC magnetic composite were biocompatible. The nanostructures characterizations were investigated by Fourier transform infrared spectroscopy, X‐ray diffraction, transmission electron microscopy and energy dispersive analysis of X‐ray techniques. Magnetic measurement revealed that the saturated magnetization of the FG‐AC nanocomposite reached 7.6 emu/g and showed the characteristics of magnetism. Abstract : An efficient method for producing stable water dispersion of magnetic Fe3 O4 nanoparticles was reported which are promising carriers for the delivery of platinum‐based anticancer drugs.